Story thread · 106 reports / 11 sources
UCB stock slides despite Bimzelx revenue beating forecasts
endpts.com · 12d
How the coverage leans
Across 11 sources · syndicated copies counted once
UCB shares dropped Thursday on investor concern that the Belgian pharma could be overpromising on its full-year forecast, even as sales of its lead drug topped analysts' expectations. The company reported Bimzelx, which is used ...
First report: REXEL : Q2 sales & H1 2026 results — markets.businessinsider.com, 15d
The coverage
- Flowserve Q2 2026 slides: bookings surge 26%, margins expand
investing.com · 12d
- Madison Air slides as investors shrug off earnings beat
seekingalpha.com · 12d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.